In Allergan, Inc. v. Teva Pharmaceuticals USA, Inc. et al, Case No. 2:15-cv-1455-WCB (EDTX October 16, 2017 Order), a Federal District Court recently invalidated several patents covering Allergan’s ...

After stirring up a tribal licensing controversy, Allergan has run into a patent setback with big-selling eye medication Restasis. A federal judge invalidated exclusive protections for the ...

Please provide your email address to receive an email when new articles are posted on . We interrupt this well-designed linear discussion of dry eye syndrome to bring you an important announcement: ...

Inspire has stopped co-promoting Restasis, the dry-eye drug launched by Allergan, according to the Triangle Business Journal. Inspire will still receive royalties on the drug at the same rate as ...

Allergan plc’s AGN shares declined almost 1% presumably due to the U.S. Supreme Court’s unfavorable ruling in a litigation related to patents covering its blockbuster eye drug, Restasis per an article ...

According to the FDA’s draft guidelines, companies wanting to make a generic version of Restasis have two options – an in vitro study or an in vivo study. The first option implies that no clinical ...

Allergan has taken intense heat lately for trying to protect its big-selling Restasis from rivals by licensing patents to a Native American tribe. But according to a new lawsuit, the company's ...

Restasis is a brand-name eye drop that’s prescribed for chronic dry eye. The medication is available in single-use and multiuse vials. Restasis is a type of immunosuppressant. Restasis is approved by ...

(Reuters) - Allergan Plc (AGN.N) on Wednesday reassured shareholders that it would return to earnings growth in 2019 after losing a major patent ruling last month on its second-most important drug, ...

Aurinia Pharmaceuticals and its dry eye drug started 2019 with a mixed bag of data from a head-to-head trial with Allergan’s blockbuster Restasis. Now, it’s unveiling results from a different ...

Please provide your email address to receive an email when new articles are posted on . TearCare outperformed Restasis in tear break-up time and meibomian gland secretion score. OSDI scores and other ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. An error has occurred. Please try again ...